Latest Intelligence on Oncology in Denmark

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Novo Nordisk/Dr Reddy's: cancer fears freeze diabetes drug

Novo Nordisk has suspended human trials of ragaglitazar, after discovering tumors in rodents that had been fed the experimental drug. The possible loss of ragaglitazar, which had been forecast peak annual sales of $1.78 billion, is Novo Nordisk's third setback this year. It also hits the drug's originator Dr Reddy's hard.

Published By Datamonitor
23 Jul 2002

« | 1 | » »|

No help is available.